Incyte’s Retifanlimab Tests US FDA’s Tolerance For Low Response Rates In Accelerated Approval
US FDA advisory committee votes 13-4 to wait for Phase III data in anal cancer, expected in 2025.
US FDA advisory committee votes 13-4 to wait for Phase III data in anal cancer, expected in 2025.